Product Images Docetaxel

The graph shows the probability of Disease-Free Survival over Time (in months) for the TAX316. No further information is available.*

The text is a description of a figure labeled "Figure 2 - TAX316 Overall Survival K-M Curve". The figure shows a graph with the x-axis labeled with "Survival Time (months)" ranging from 0 to 66 and the y-axis labeled with "Survival Probability (%)" ranging from 0 to 100. The graph displays a curve indicating the overall survival probability for the given data.*

This is a graph, labeled "Figure 3 - TAX317 Survival K-M Curves", that compares the survival of patients receiving Docetaxel 75mg/m² to those receiving best supportive care. The x-axis represents survival time in months, while the y-axis represents cumulative probability. The graph shows that overall survival of patients receiving Docetaxel was higher than those receiving best supportive care, with a Log-rank p-value of 0.010.*

The text is describing a figure labeled as "Figure 4", showcasing a comparison of TAX320 Survival K-M Curves in patients treated with Docetaxel 75 mg/m? versus Vinorelbine or Ifosfamide Control. The survival data is presented graphically on an x-axis listing survival time in months and a y-axis displaying overall survival percentage. The results show a Log-rank p-value of 0.138 and the figure appears to have 6 curves.*

This is a graph of survival probability over a period of 30 months represented in a K-M curve with time displayed in months on the x-axis and survival probability on the y-axis. The plot shows the graph for the TAX327 group survival rate where the probability of survival decreases over time.*

This is a graph or figure from the Gastric Cancer Study (TAX325) showing the Time to Progression K-M Curve. The x-axis represents time in months, while the y-axis represents probability as a percentage. Other than the numerical and graphical elements, no additional information is available from this text.*

This is a graph showing the overall survival probability (%) of a group of patients in a clinical trial labeled "TAX323". The X-axis represents survival time in months and the Y-axis represents the probability of survival. The plot indicates the probability of survival at different time points during the trial. The data is presented as a K-M (Kaplan-Meier) curve, which is a common method to estimate survival rates. The curve shows that at the start of the trial, all patients had a 100% chance of survival, but over time, some patients experienced a decrease in survival probability. The data is limited to the information on this graph.*

Docetaxel Injection, USP is a cytotoxic agent used for intravenous use only. It comes in a single-dose vial containing 20 mg/2 ml of solution. The medication is distributed by Hospira, Inc. and is ready to be added to infusion after checking the concentration prior to preparation. Unused portions must be discarded. The product should be stored at 20°C to 25°C. The NDC code is 0409-0201-02.*

This is a description for a Docetaxel Injection, USP medication. It is a Multiple-dose Vial that contains 8 ml of liquid, to be administered intravenously by a healthcare professional. Each ml of the liquid contains 10 mg Docetaxel and other components such as Polysorbate 80 NF, Anhydrous Citric Acid USP, Dehydrated Alcohol USP, and Polyethylene Glycol 300 NF. The medication must be stored between 20°C to 25°C and kept away from light as it is a cytotoxic agent. Dosage information is provided in a package insert.*

This is a description for a medication called Docetaxel Injection, USP. It comes in a multiple-dose vial of 80mg/8mL (10mg/ml) and is ready to add to an infusion solution. Each mL contains 10mg of Docetaxel along with Polysorbate 80 NF, 4mg Anhydrous Citric Acid USP, 23% v/v Dehydrated Alcohol USP, q.5. with Polyethylene Glycol 300 NF. The package insert must be consulted for dosage information, directions for use, and handling. The medication must be used intravenously, and caution should be taken as it is a cytotoxic agent. The vial should be kept out of reach of children and stored between 20°C and 25°C (68°F to 77°F). After first use, it is stable for up to 28 days when stored between 2°C and 8°C (36°F and 45°F) and protected from light.*

This is a description of a medicine called Docetaxel which is an injection used intravenously. The injection contains 10 mg Docetaxel, 260 mg Polysorbate, 80 NF, 4 mg Anhydrous Citric Acid USP, 23% /v Dehydrated Alcohol USP and Polyethylene Glycol 300 NF. The injection is contained in a 16 mL vial which must be stored in temperatures between 20°C to 25°C and protected from light. It is a cytotoxic agent, and the dosage should be taken as prescribed in the insert. It is distributed by Hospira, Inc. and is for intravenous use only. Preparation instructions are noted on the package insert.*

This is a medication called Docetaxel Injection, to be used intravenously with caution as it is a cytotoxic agent. It comes in a 160mg/16mL (10mg/mL) vial with instructions to check concentration prior to preparation and to see package insert for complete instructions. The vials are stable for up to 28 days when stored between 2°C and 8°C and protected from light after first use. It contains Docetaxel, Polysorbate 80 NF, anhydrous Citric Acid USP, dehydrated Alcohol USP, and Polyethylene Glycol 300 NF. The package insert should be consulted for dosage information, directions for use, and handling. The medication comes in a one-vial formulation, and the original package should be stored at a controlled room temperature between 20°C to 25°C.*